Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
93.86
+1.06 (1.14%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $11.16B in the quarter ending March 31, 2026, with 7.78% growth. This brings the company's revenue in the last twelve months to $45.13B, up 6.59% year-over-year. In the year 2025, Abbott Laboratories had annual revenue of $44.33B with 5.67% growth.
Revenue (ttm)
$45.13B
Revenue Growth
+6.59%
P/S Ratio
3.62
Revenue / Employee
$392,470
Employees
115,000
Market Cap
163.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.33B | 2.38B | 5.67% |
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medtronic | 35.48B |
| Stryker | 25.12B |
| Koninklijke Philips | 20.94B |
| GE HealthCare Technologies | 20.63B |
| Boston Scientific | 20.61B |
| Zimmer Biomet Holdings | 8.23B |
| Edwards Lifesciences | 6.30B |
| Smith & Nephew | 6.16B |
ABT News
- 19 hours ago - Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform - PRNewsWire
- 3 days ago - Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 - PRNewsWire
- 11 days ago - New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test - PRNewsWire
- 11 days ago - Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings - Benzinga
- 12 days ago - Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks - Benzinga
- 12 days ago - Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales - WSJ
- 12 days ago - Abbott Laboratories Earnings Call Transcript: Q1 2026 - Transcripts
- 12 days ago - Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting. - Barrons